Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (ZTS) drives innovation in animal health as the global leader in veterinary pharmaceuticals and diagnostics. This news hub provides investors and industry professionals with essential updates on developments impacting companion animal care and livestock health systems.
Access curated press releases and analysis covering product approvals, research breakthroughs, and financial performance. Our repository includes updates on vaccine innovations, parasiticides, diagnostic tools, and strategic partnerships across 100+ markets. Monitor earnings announcements, manufacturing expansions, and regulatory milestones that shape this $80B sector.
Bookmark this page for streamlined tracking of Zoetis' operational progress in developing solutions for pets and farm animals. Return regularly to stay informed about initiatives affecting animal welfare standards and agricultural productivity worldwide.
Zoetis reported second-quarter 2022 revenue of $2.1 billion, a 5% increase year-over-year. Net income reached $529 million, equating to $1.12 per diluted share, marking a 3% rise. Operationally, revenue grew 8% and adjusted net income rose 9%, excluding foreign currency impacts. The company updated its 2022 guidance, projecting revenue between $8.225 billion and $8.325 billion and diluted EPS of $4.65 to $4.75 on a reported basis.
Despite growth, Zoetis faces challenges including foreign exchange fluctuations and commodity competition.
Zoetis Inc (NYSE: ZTS) appointed Vanessa Broadhurst, Executive VP at Johnson & Johnson, to its Board of Directors, expanding the board from 11 to 12 members. Broadhurst brings extensive experience in consumer insights and direct-to-consumer marketing, set to enhance Zoetis' focus on pet owners. CEO Kristin Peck praised her strategic leadership and consumer healthcare expertise. Broadhurst is recognized as one of the "2022 Most Influential Black Executives in Corporate America" and will also serve on the Quality and Innovation Committee.
Zoetis Inc (NYSE:ZTS) is scheduled to host a webcast and conference call on August 4, 2022, at 8:30 a.m. ET. CEO Kristin Peck and CFO Wetteny Joseph will discuss the second quarter 2022 financial results. The public can access the live webcast via Zoetis' investor website, with a replay available post-event. Zoetis, a leader in animal health, reported $7.8 billion in revenue for 2021 and employs approximately 12,100 individuals globally.
Zoetis (NYSE:ZTS) has completed the acquisition of Basepaws, a petcare genetics company specializing in genetic testing and health risk assessments for pets. This strategic move enhances Zoetis' precision animal health portfolio, allowing for better disease detection and management for pet owners and veterinarians. Financial details of the acquisition were not disclosed. Zoetis aims to leverage Basepaws' insights for future innovations in petcare, supporting their commitment to advancing animal health.
Zoetis (NYSE:ZTS), the global leader in animal health, announced participation in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022. Wetteny Joseph, CFO, will present at 4:20 p.m. ET. Investors can access a live audio webcast at investor.zoetis.com/events-presentations. A replay will be available post-event. In 2021, Zoetis generated revenue of $7.8 billion, employing approximately 12,100 staff worldwide, showcasing its commitment to advancing animal care.
Zoetis Inc. (NYSE:ZTS) announced the acquisition of Basepaws, a petcare genetics company known for its genetic testing and health risk assessments for cats. This strategic move aims to enhance Zoetis’ precision animal health portfolio and R&D capabilities, leveraging Basepaws’ extensive genomic and microbiome databases. Financial details of the acquisition were not disclosed. The partnership is expected to boost innovation in petcare, improving health management and overall quality of care for pets.
Zoetis (NYSE:ZTS) will participate in the Stifel 2022 Jaws and Paws Conference on June 1, 2022, with Glenn David, Executive Vice President, presenting at 4:10 p.m. ET. Investors can access a live audio webcast of the presentation through the company's investor relations website, where a replay will also be available. Zoetis is a leading animal health company, generating $7.8 billion in revenue in 2021, focused on advancing animal care worldwide. The company operates in over 100 countries with a dedicated workforce of approximately 12,100 employees.
Zoetis Inc. (NYSE:ZTS) has declared a quarterly dividend of
Zoetis reported Q1 2022 revenue of $2.0 billion, up 6% year-over-year, and net income of $595 million, reflecting a 6% increase. Adjusted net income reached $625 million, or $1.32 per diluted share, representing a 4% rise. Operationally, revenue grew 9% and adjusted net income 8%, excluding foreign exchange impacts. The company updated its full-year revenue guidance to $8.225 - $8.375 billion primarily due to unfavorable foreign exchange rates. Despite uncertainties from global challenges, Zoetis remains confident in its operational growth.
FAQ
What is the current stock price of Zoetis (ZTS)?
What is the market cap of Zoetis (ZTS)?
